Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ANTI-IL12/23 or ANTI-IL23 - risankizumab
(D11052)		----[1] 96 💬
2Risankizumab
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[4] 37, 96, 97, 271 💬
3Risankizumab 10 MG/ML
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
4Risankizumab 180 MG SC
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
5Risankizumab 600 MG IV
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
6Risankizumab 90 MG/ML
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
7Risankizumab IV
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
8Risankizumab SC
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
9Risankizumab-800CW 15 MG
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
10Risankizumab-800CW 25 MG
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
11Risankizumab-800CW 4.5 MG
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
12Risankizumab-800CW optimal dose
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬